Antiviral Resistance and Correlates of Virologic Failure in the first Cohort of HIV-Infected Children Gaining Access to Structured Antiretroviral Therapy in Lima, Peru: A Cross-Sectional Analysis

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Rath, Barbara A ^a,b,h   von Kleist, Max ^c   Castillo, Maria E ^d   Kolevic, Lenka ^d   Caballero, Patricia ^e   Soto Castellares, Giselle ^f   Amedee, Angela M ^g   Robinson, James E ^b   Katzenstein, David K ^h   Van Dyke, Russell B ^b   Oberhelman, Richard A ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

^d UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f ASOCIACIÓN BENÉFICA PRISMA   (Peru)

^g LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DNA; LAMIVUDINE; NELFINAVIR; RNA; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; BLOOD ANALYSIS; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONSENSUS SEQUENCE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE CLASSIFICATION; DRIED BLOOD SPOT TESTING; DRUG EXPOSURE; DRUG MONITORING; DRUG TREATMENT FAILURE; FEMALE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HEALTH CARE ACCESS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MALE; OLIGONUCLEOTIDE LIGATION ASSAY; PERIPHERAL BLOOD MONONUCLEAR CELL; PERU; PRESCHOOL CHILD; QUESTIONNAIRE; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT OUTCOME; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS MUTATION;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; DRUG RESISTANCE, VIRAL; GENES, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; INFANT; MUTATION; PERU; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; VIRAL LOAD;

EID: 84871688956     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-1     Document Type: Article

References (52)

1. UNAIDS Report on the Global AIDS Epidemic - Executive Summary 2004, 1-22. Geneva, Switzerland: UNAIDS - Joint United Nations Programme on HIV/AIDS: Edited by HIV/AIDS U-JUNPo, UNAIDS.
2. Hainaut M, Ducarme M, Schandene L, Peltier CA, Marissens D, Zissis G, Mascart F, Levy J. Age-related immune reconstitution during highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 2003, 22(1):62-69. 10.1097/00006454-200301000-00016, 12544411.
3. Curioso WH, Kepka D, Cabello R, Segura P, Kurth AE. Understanding the facilitators and barriers of antiretroviral adherence in Peru: a qualitative study. BMC Public Health 2010, 10:13. 10.1186/1471-2458-10-13, 2820472, 20070889.
4. Franke MF, Murray MB, Munoz M, Hernandez-Diaz S, Sebastian JL, Atwood S, Caldas A, Bayona J, Shin SS. Food Insufficiency is a Risk Factor for Suboptimal Antiretroviral Therapy Adherence among HIV-Infected Adults in Urban Peru. AIDS Behav 2011, 15(7):1483-1489. 10.1007/s10461-010-9789-6, 3377162, 20714923.
5. Franke MF, Munoz M, Finnegan K, Zeladita J, Sebastian JL, Bayona JN, Shin SS. Validation and abbreviation of an HIV stigma scale in an adult spanish-speaking population in urban Peru. AIDS Behav 2010, 14(1):189-199. 10.1007/s10461-008-9474-1, 20838872.
6. Esteban PM, Thahn TG, Bravo JF, Roca LK, Quispe NM, Montano SM, Zunt JR. Malnutrition associated with increased risk of peripheral neuropathy in Peruvian children with HIV infection. J Acquir Immune Defic Syndr 2009, 52(5):656-658.
7. Willig JH, Echevarria J, Westfall AO, Iglesias D, Henostroza G, Seas C, Mugavero MJ, Allison J, Paz J, Hernandez F, et al. Durability of initial antiretroviral therapy in a resource-constrained setting and the potential need for zidovudine weight-based dosing. J Acquir Immune Defic Syndr 2010, 53(2):215-221. 10.1097/QAI.0b013e3181bc0f10, 20104120.
8. Shin S, Munoz M, Zeladita J, Slavin S, Caldas A, Sanchez E, Callacna M, Rojas C, Arevalo J, Sebastian JL, et al. How does directly observed therapy work? The mechanisms and impact of a comprehensive directly observed therapy intervention of highly active antiretroviral therapy in Peru. Health Soc Care Community 2011, 19(3):261-271. 10.1111/j.1365-2524.2010.00968.x, 21143333.
9. Reynolds NR, Testa MA, Marc LG, Chesney MA, Neidig JL, Smith SR, Vella S, Robbins GK. Factors influencing medication adherence beliefs and self-efficacy in persons naive to antiretroviral therapy: a multicenter, cross-sectional study. AIDS Behav 2004, 8(2):141-150.
10. Pontali E, Feasi M, Toscanini F, Bassetti M, De Gol P, Nuzzolese A, Bassetti D. Adherence to combination antiretroviral treatment in children. HIV Clin Trials 2001, 2(6):466-473. 10.1310/7BNT-UTL0-UPPF-CA9H, 11742434.
11. Cesar C, Shepherd BE, Krolewiecki AJ, Fink VI, Schechter M, Tuboi SH, Wolff M, Pape JW, Leger P, Padgett D, et al. Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America. PLoS One 2010, 5(6):e10490. 10.1371/journal.pone.0010490, 2879360, 20531956.
12. Munoz M, Bayona J, Sanchez E, Arevalo J, Sebastian JL, Arteaga F, Guerra D, Zeladita J, Espiritu B, Wong M, et al. Matching Social Support to Individual Needs: A Community-Based Intervention to Improve HIV Treatment Adherence in a Resource-Poor Setting. AIDS Behav 2011, 15(7):1454-1464. 10.1007/s10461-010-9697-9, 20383572.
13. Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, Musoke P, Fleming T. Glenn Fowler M, Mofenson LM et al.: Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001, 15(15):1951-1957. 10.1097/00002030-200110190-00006, 11600822.
14. Wang ME, Castillo ME, Montano SM, Zunt JR. Immune reconstitution inflammatory syndrome in human immunodeficiency virus-infected children in Peru. Pediatr Infect Dis J 2009, 28(10):900-903. 10.1097/INF.0b013e3181a4b7fa, 3514443, 19687769.
15. MINSA Aprobación de la directiva 2002, In. Lima, Peru: Ministerio de Salud del Peru (MINSA): Tratamiento Antiretroviral en los niños infectados por el VIH, MINSA.
16. MINSA Guía Nacional de Manejo del Niño infectado por el VIH 1999, In. Lima: Ministerio de Salud del Peru (MINSA), MINSA.
17. DIRECTIVA No. 020 - 2003-MINSA/DGSP-DEAIS-V.01 2003, DIRECTIVA No. 020 - 2003-MINSA/DGSP-DEAIS-V.01., http://www.sgcnnavih.cepesju.org/Normativas/DIRECTIVA_020-2003-MINSA_DGSP-DEAIS-V.01.pdf
18. Soria J, Bull M, Mitchell C, Rosa AL, Dross S, Kraft K, Coombs R, Ticona E, Frenkel L. Transmitted HIV Resistance to First-Line Antiretroviral Therapy in Lima. AIDS Res Hum Retroviruses 2012, 28(4):333-8. 10.1089/aid.2011.0131, 21819256.
19. Ellis GM, Mahalanabis M, Beck IA, Pepper G, Wright A, Hamilton S, Holte S, Naugler WE, Pawluk DM, Li CC, et al. Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma. J Clin Microbiol 2004, 42(8):3670-3674. 10.1128/JCM.42.8.3670-3674.2004, 497615, 15297515.
20. Schinazi RF, Schlueter-Wirtz S, Stuyver L. Early detection of mixed mutations selected by antiretroviral agents in HIV-infected primary human lymphocytes. Antivir Chem Chemother 2001, 12(Suppl 1):61-65.
21. Frenkel LM, Wagner LE, Atwood SM, Cummins TJ, Dewhurst S. Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to, and didanosine. J Clin Microbiol 1995, 33(2):342-347. 227945, 7714190.
22. Cassol SA, Read S, Weniger BG, Pilon R, Leung B, Mo T. Diagnosis and Direct Automated Sequencing of HIV-1 From Dried Blood Spots (DBS) Collected on Filter Paper. Methods Mol Med 1999, 17:125-138.
23. Sherman GG, Stevens G, Jones SA, Horsfield P, Stevens WS. Dried blood spots improve access to HIV diagnosis and care for infants in low-resource settings. J Acquir Immune Defic Syndr 2005, 38(5):615-617. 10.1097/01.qai.0000143604.71857.5d, 15793374.
24. Youngpairoj AS, Masciotra S, Garrido C, Zahonero N, de Mendoza C, Garcia-Lerma JG. HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4 degrees C. J Antimicrob Chemother 2008, 61(6):1217-1220. 10.1093/jac/dkn100, 2386080, 18344550.
25. Mitchell C, Jennings C, Brambilla D, Aldrovandi G, Amedee AM, Beck I, Bremer JW, Coombs R, Decker D, Fiscus S, et al. Diminished human immunodeficiency virus type 1 DNA yield from dried blood spots after storage in a humid incubator at 37 degrees C compared to -20 degrees C. J Clin Microbiol 2008, 46(9):2945-2949. 10.1128/JCM.00359-08, 2546762, 18614660.
26. Mitchell C, Kraft K, Peterson D, Frenkel L. Cross-contamination during processing of dried blood spots used for rapid diagnosis of HIV-1 infection of infants is rare and avoidable. J Virol Methods 2010, 163(2):489-491. 10.1016/j.jviromet.2009.10.016, 2815236, 19878694.
27. CDC Revised Classification System for Human Immunodeficiency Virus Infection in Children Less Than 13 Years of Age. MMWR 1994, 43(12):1-10. CDC.
28. Farley JJ, Montepiedra G, Storm D, Sirois PA, Malee K, Garvie P, Kammerer B, Naar-King S, Nichols S. Assessment of adherence to antiretroviral therapy in perinatally HIV-infected children and youth using self-report measures and pill count. J Dev Behav Pediatr 2008, 29(5):377-384. 10.1097/DBP.0b013e3181856d22, 18714204.
29. Naar-King S, Montepiedra G, Nichols S, Farley J, Garvie PA, Kammerer B, Malee K, Sirois PA, Storm D. Allocation of family responsibility for illness management in pediatric HIV. J Pediatr Psychol 2009, 34(2):187-194. 2722122, 18586756.
30. Henning TR, Lacour N, Amedee AM. Efficient methodologies for sensitive HIV-1 RNA quantitation from plasma and vaginal secretions. J Clin Virol 2009, 46(4):309-313. 10.1016/j.jcv.2009.08.015, 19783472.
31. Beck IA, Mahalanabis M, Pepper G, Wright A, Hamilton S, Langston E, Frenkel LM. Rapid and sensitive oligonucleotide ligation assay for detection of mutations in human immunodeficiency virus type 1 associated with high-level resistance to protease inhibitors. J Clin Microbiol 2002, 40(4):1413-1419. 10.1128/JCM.40.4.1413-1419.2002, 140364, 11923366.
32. Shafer RW, Hertogs K, Zolopa AR, Warford A, Bloor S, Betts BJ, Merigan TC, Harrigan R, Larder BA. High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients. J Clin Microbiol 2001, 39(4):1522-1529. 10.1128/JCM.39.4.1522-1529.2001, 87964, 11283081.
33. Child Growth Standards: Child Growth Standards:., http://www.who.int/childgrowth/standards/weight_for_age/en/index.html
34. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer R, Wensing AM, Richman DD. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011, 19(4):156-164.
35. Crabtree-Ramirez B, Caro-Vega Y, Shepherd BE, Wehbe F, Cesar C, Cortes C, Padgett D, Koenig S, Gotuzzo E, Cahn P, et al. Cross-sectional analysis of late HAART initiation in Latin America and the Caribbean: late testers and late presenters. PLoS One 2011, 6(5):e20272. 10.1371/journal.pone.0020272, 3102699, 21637802.
36. Alarcon JO, Freimanis-Hance L, Krauss M, Reyes MF, Cardoso CA, Mussi-Pinhata MM, Cardoso E, Alarcon JO, Freimanis-Hance L, Krauss M, Reyes MF, Cardoso CA, Mussi-Pinhata MM, Cardoso E, Alarcon JO, Freimanis-Hance L, Krauss M, Reyes MF, Cardoso CA, Mussi-Pinhata MM, Cardoso E. Opportunistic and other infections in HIV-infected Children in Latin America compared to a similar cohort in the United States. AIDS Res Hum Retroviruses 2012, 28(3):282-8. 10.1089/aid.2011.0057, 21902581.
37. Patel K, Hernan MA, Williams PL, Seeger JD, McIntosh K, Dyke RB, Seage GR. Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting. Clin Infect Dis 2008, 46(11):1751-1760. 10.1086/587900, 3154876, 18426371.
38. Feucht UD, Forsyth B, Kruger M. False-positive HIV DNA PCR testing of infants: Implications in a changing epidemic. S Afr Med J 2012, 102(3):149-152.
39. Frank M, von Kleist M, Kunz A, Harms G, Schutte C, Kloft C. Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes. Antimicrobial agents and chemotherapy 2011, 55(12):5529-5540. 10.1128/AAC.00741-11, 3232796, 21947390.
40. Garcia PJ, Vargas JH, Caballero NP, Calle VJ, Bayer AM. An e-health driven laboratory information system to support HIV treatment in Peru: E-quity for laboratory personnel, health providers and people living with HIV. BMC Med Inform Decis Mak 2009, 9:50. 10.1186/1472-6947-9-50, 2797768, 20003281.
41. MINSA A Step Forward in the FIght Against AIDS 2006, In. Lima: Ministerio de Salud del Peru (MINSA): The first two years of universal access to antiretroviral treatment in Peru, MINSA.
42. Aldridge RW, Iglesias D, Caceres CF, Miranda JJ. Determining a cost effective intervention response to HIV/AIDS in Peru. BMC Public Health 2009, 9:352. 10.1186/1471-2458-9-352, 2761404, 19765304.
43. Tuboi SH, Schechter M, McGowan CC, Cesar C, Krolewiecki A, Cahn P, Wolff M, Pape JW, Padgett D, Madero JS, et al. Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean. J Acquir Immune Defic Syndr 2009, 51(5):615-623. 10.1097/QAI.0b013e3181a44f0a, 2780368, 19430306.
44. Clark JL, Long CM, Giron JM, Cuadros JA, Caceres CF, Coates TJ, Klausner JD. Partner notification for sexually transmitted diseases in Peru: knowledge, attitudes, and practices in a high-risk community. Sex Transm Dis 2007, 34(5):309-313.
45. Furin JJ, Behforouz HL, Shin SS, Mukherjee JS, Bayona J, Farmer PE, Kim JY, Keshavjee S. Expanding global HIV treatment: case studies from the field. Ann N Y Acad Sci 2008, 1136:12-20. 10.1196/annals.1425.004, 17954668.
46. Curioso WH, Kurth AE. Access, use and perceptions regarding Internet, cell phones and PDAs as a means for health promotion for people living with HIV in Peru. BMC Med Inform Decis Mak 2007, 7:24. 10.1186/1472-6947-7-24, 2048945, 17850656.
47. Bastos FI, Caceres C, Galvao J, Veras MA, Castilho EA. AIDS in Latin America: assessing the current status of the epidemic and the ongoing response. Int J Epidemiol 2008, 37(4):729-737.
48. Curioso WH, Kurth AE, Cabello R, Segura P, Berry DL. Usability evaluation of Personal Digital Assistants (PDAs) to support HIV treatment adherence and safer sex behavior in Peru. AMIA Annu Symp Proc 2008, 918.
49. Kurth AE, Curioso WH, Ngugi E, McClelland L, Segura P, Cabello R, Berry DL. Personal digital assistants for HIV treatment adherence, safer sex behavior support, and provider training in resource-constrained settings. AMIA Annu Symp Proc 2007, 1018.
50. Lopez De Castilla D, Verdonck K, Otero L, Iglesias D, Echevarria J, Lut L, Gotuzzo E, Seas C. Predictors of CD4+ cell count response and of adverse outcome among HIV-infected patients receiving highly active antiretroviral therapy in a public hospital in Peru. Int J Infect Dis 2008, 12(3):325-331. 10.1016/j.ijid.2007.09.008, 18546542.
51. Corey DM, Kim HW, Salazar R, Illescas R, Villena J, Gutierrez L, Sanchez J, Tabet SR. Brief report: effectiveness of combination antiretroviral therapy on survival and opportunistic infections in a developing world setting: an observational cohort study. J Acquir Immune Defic Syndr 2007, 44(4):451-455. 10.1097/QAI.0b013e31802f8512, 17195766.
52. Cohen J. HIV/AIDS: Latin America & Caribbean. Peru: universal access: more goal than reality. Science 2006, 313(5786):489. 10.1126/science.313.5786.489, 16873658.